|Videos|April 15, 2021
Identifying Patients Appropriate for Front Line Maintenance Therapy in Advanced Ovarian Cancer
Author(s)Rebecca Previs, MD
Dr. Rebecca Previs talks about when first line maintenance therapy is appropriate and which patients should be presented with this option.
Advertisement
Episodes in this series
Advertisement
Related to this article
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
5